V

Verismo Therapeutics

14 employees

Verismo Therapeutics develops novel chimeric antigen receptors (CARs) that enhance T-cell-based cellular immunotherapy for cancer.

Basic info

Industry

biotechnology research

Sectors

Biotechnology
Therapeutics
Solid Tumor
Immuno-Oncology
Cell Therapy
CAR-T
Medical
Health Care
KIR-CAR Platform

Date founded

2020

Funding rounds raised

Total raised

$17M

from 1 investors over 1 rounds

V

Verismo Therapeutics raised $17M on July 18, 2023

Investors: Hong Leong Group

FAQ